Nevertheless, the company was inching its way towards profitability. Prospects for Ligand's future appeared quite bright. Dr. Harriman joined Ligand in 2017 with the acquisition of Crystal Bioscience, where he was co-Founder and CSO, contributing key technology to enable the development of the OmniChicken platform, and overseeing its implementation in corporate partnerships. Organa and Bristol-Myers Squibb both signed pacts in 2000. Ligand gave its new sales force more business in 1995 by acquiring the Canadian rights to sell Photofrin, a bladder cancer drug. Moreover, Ligand was still able to attract major pharmaceuticals to enter into collaborative research agreements. A year later the company shifted its emphasis to IR work, licensing technology from the Salk Institute. Robinson, who had only planned on running Ligand for five years, was still at the helm after ten. magazine’s 2019 Most Influential Corporate Directors list. He has overseen the continued strengthening of capabilities in structure and fragment-based drug discovery. Welcome to Ligand Pharmaceuticals. His mother struggled to support the family of seven from the wages she earned as a government clerk, forcing Robinson to go to work at the age of 12. Should clinical trials show that Targretin was effective against breast cancer, however, that number would likely grow to $300 million in annual sales.Like Birndorf, Robinson also took an unusual path to becoming a chief executive. Prior to joining Ligand in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel Laboratories, Inc. division of GlaxoSmithKline (GSK). Chief Financial Officer, Vice President of Finance and Strategy, to succeed John Sharp, who is leaving at the end of this month for a position with a private company.
Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs.
The position required a heavy travel schedule, as Robinson commuted from his home in Connecticut to offices in Columbus, Ohio, and Milan, Italy. Please check your download folder.If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page.
A few days later Ligand acquired Seragen Inc., a Boston biotech, in a $35 million cash and stock transaction.
Dr. Wood joined Ligand in 2018, following Ligand’s acquisition of Vernalis. Dr. Wood has been Managing Director of Vernalis Research since 2019, and previously held the role of Research Director from 2004. Marschke joined Ligand in 1994 and is currently the head of Biology and Scientific Affairs.
She was promoted to Senior Vice President, Human Resources in 2018 and to Vice President, Human Resources in 2007. Vajda joined Ligand in 2002 and is the head of preclinical research and development. Pipkin joined Ligand in 2011, following Ligand's acquisition of CyDex Pharmaceuticals.
Ontak was a good fit for Ligand because of the CTCL drugs it already had in clinical trials, Targetin gel and Targetin capsules. Dr. Marschke received a PhD in molecular and cellular pathobiology from the Bowman Gray School of Medicine at Wake Forest University and held a postdoctoral research position in the Laboratories for Reproductive Biology at the University of North Carolina, Chapel Hill. Six months later, however, he was returned to Australia and was able to complete his M.B.A. before embarking on a number of stops for Abbott. Ligand Pharmaceuticals Incorporated June 1, 2020 About Ligand Pharmaceuticals. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IR) and Signal Transducers and Activators of Transcription (STATs). Dr. Pipkin's responsibilities include development of new applications, intellectual property and products utilizing Captisol both internally and assisting clients, whether the application involves new molecular entities, an Orphan designated drug or reformulations of existing drugs for lifecycle management via the 505(b)(2) regulatory pathway.
Toy Story Oscar, Olivia Buckland Say Yes To The Dress, Japanese Ceramic Knives, KANA-BOON Nademo Nedari Lyrics Romaji, Destroyer Have We Met (Vinyl), Free Parking Tempe Town Lake, Fried Chicken Day Deals, Chandler Weather 10-day, Dress With Shirt Over, Bob Van Dijk Tencent, Nantucket Sailors Bracelet, Stewart Francis Dvd, Vsphere Client Linux, Mr Noodle Death, Messy Marv Now, Ryzen 7 1700x Vs Ryzen 5 2600, Dell Emc Storage Portfolio Pdf, Realty Income Dividend Yield History, Raoul Bellanova Fifa 20, Nitecore Headlamp Nu20, Lynn Ferguson New York, Walmart Uvalde, Tx Phone Number, Procore Continuing Education, Good Wishes For A Friend, Iit Kharagpur Notable Alumni, Whitecaps Vs Cavalry Twitter, Cassi Davis Married, Walter Keane Paintings, Phoenix Marriott Resort Tempe At The Buttes,